INCIDENCE
The true incidence and prevalence of primary dysmenorrhea has not been clearly eSlabJished. It varies from community to community and from co untry to country. Estimates of prim ary dysmenorrhea run as high !IS 50% in post pubescent females and approximately 10% of th ose women are incapacitated for I to.3 days each month.
It is the greatest single cause of lost working and school days among young women, with estimates of more than 140 million working hours lost annually '. With the increase of women in the nalion's work force:, the loss will be greatly compounded but fortunate ly the availability of new treatments will probably reduce the loss. At an individual level. dysmenorrhea may generate sufficient fear in anticipation of the next menstruation such that menial health during the intermenstrual phase may be severely compromised. Therefore, it is not too difficult to visualize that marital and domestic upheavals may ensue.
CLINICAL FEATU R ES
Primary dysmenorrhea occurs almost invariably in ovulatory cycles and usually appears at or within 6·12 months after menarche when ovulatory cycles are established . However. it may sel in with the first menstrual now at menarche. Thediagnosis of primary dysmenorrhea made on women with a novula tory cycles is suspect since these are more likely to be secondary dysmenorrhea. Dysmenorrhea sta rting more than two years after the menarche should arouse suspicion of secondary dysmenorrhea a nd a high likelihood of endomet riosis.
In primary dysmenorrhea, the pains, which afe spasmodic in character, are strongest over the lower abdomen, but may radiale 10 the back and along the thighs. Systemic symptoms include nausea , vomiting, diarrhea. headache, fatigue, nervousness, dizziness. and in some cases even syncope and collapse. Pelvic pain is accompanied by one or more systemic symptoms in more than SO percent of dysmenorrheic subjects . I These sym ptoms include lower backache(60 percent), nausea and/ or vomiting (89 percent), diarrhea (60 percent), headache (45 percent) and tiredness (805 percent). The pains usually start some hours before commencement of visible vaginal bleeding and are most severe on the first day of menstruation, when the woman may be entirely incapacitated from normal activity. The symptoms may last from a few hours to one day but seldom exceed two to three days. In some patients there is a tendency towards spontaneous alleviation of primary dysmenorrhea after the first child birth but the relief is only temporary for many patients. Advancing age is a beUer alleviating factor but even this is not invariable.
Pelvic examination is negative in primary dysmenorrhea. It is important that a rectovaginal examination is a sine-qua-non in patients with dysmenorrhea in order to rule out any palpable nodularities or thickenings in the cul-de-sac, uterosacral ligaments and rectovaginal septum which are common sites for endometriosis.
DIAGNOSIS AND INV£STlGATIONS
The diagnosis of primary dysmenorrhea shouJd be made on its positive clinical features aod the important hallmarks are a) the initial onset dates back to the menarche. b) the duration of the dysmenorrhea is usually up to only hours with the pain Slart ing usually after the onset of menstrual now o r only a few hours prior to that, c) the charocrer of the pain is cramping or labor-like and d) pelvic examination (including rectovaginal examination) is normal. Differential diagnosis of primary dysmenorrhea includes all the causes of secondary dysmenorrhea which are listed in table I , but a maj or consideration is en d ometriosis. which can mimic primary dysmenorrhea very closely. In patients who have a family history of endometriosis in a mother or sister and thus have a higher risk of having endometriosis,} Iaparoscopy should be undertaken ea.rly to confirm or rule OUI endomet riosis. Although the age of onset of the dysmenorrhea is often a helpfUl feature which distinguishes primary from secondary dysmenorrhea, endometriosis has been know to occur soon after the onset of menarche. A history of recurrent pelvic inflammatory disease, irregular menstruaJ cycles especially associated with anovulation, menorrhagia, the use of an intrauterine device (IUD) and infertility are helpful features in the history which may point towards seco ndary dysmenorrhea or even the underlying cause of the secondary dysmenorrhea .
Investigations that may be useful in assisting with the diagnosi s and cause of the secondary In the put, many psychological theories have been advanced as the basis for primary dysmenorrhea. However, these studies have established no abnormality in behaviour or contributory psychological factors which are present prior to the development of the disorder. Naturally, with monthly incapacitation and pain, these patients can develop psychological reactions. both to their disorder and their environment. One consideration is the individual response 10 the mechanism of pain induced by the biochemical di30rder, Hence, any manipulation of psychological factors is more likely to influence the response to pain rather than totally remove the biochemical duorder responsible for the pain .
b. Endocrine Factor
The only proven endocrine factor is the occurrence of primary dysmenorrhea in ovulatory cycles. In anovulatory cycles and in women on the ora l contraceptive pill, primary dysmenorrhea does not occur. Thus, in dysmenorrhea associated with anovulatory cycl~, careful examination for a pelvic pathology must be perfonned . A recent investigation' indicated circulating vasopressin levels were: elevated in dysmenorrheic women during menstruation when compared to nondysmenorrheic women . The evidence is rather preliminary and since the vasopressin levels were not determined before: the onset of menstruation, it is unclear whether the increased vasopressin levels are secondary to the onset of menstruation or precede it. c. Prostaglandins and Myometrial Activity At present it is thought that in primary dysmenorrhea there: is Increased abnormal uterine activity, which is secondary to increased levels of prostaglandins produced and released by the endometriaJ tissue at the time of menstruat ion.o The cause of this increased prostaglandin production and release is 81 present unknown. Because of the hypercontractility of the uterus at menstruation in women with primary dysmenorrhea, blood now to the uterus is compromised and uterine ischaemia occurs Thus. the pain in primary dysmenorrhea is thought to be due to 3 factors: a) increased abnormal uterine activity, b) uterine ischaemia . and c) sensi tization of the nerve terminals to proslaglandins and their intermediates by lowering the threshold ofthesc nervc terminals to the action of chemical and physical stimul i. arachidonic acid th rough the action of several enzymes which are collectively termed proslaglandin synthetase. In the initial step, arachidonic acid is converted to cyclic endoperoxides through thc action of the enzyme cycJooxygenase. Subsequently the cyclic endoperoxides are converted in t o prostaglandins E2 and F2 C1 through the action of Isomerase and reouctase . 1 rauma which IS occurnng at the onset of menstruation together with the increased avallabliity of arachidonic acid. are importan t factors that will sti mulate the ge neration and release of prostaglandin s. Prostaglandin sy ntheta se inhibitors act by inhibiting the prostaglandins synthetase enzymes and therefore blocking the production of prostaglandins. The evidence for the role of prostaglandins in the pathophysiology of primary dysmenorrhea can be summarized as follows.
I . The side ~ffecls of proslaglandin F2o. administration both for termination of midtrimesur pregna ncy and induction of labor at term, include nausea, diarrhea, headache. vomiting and uterine cramps, which are essentially similar to the symptoms of primary dysmenorrhea. 
P ROSTAGLAND IN SYNTH ETASE INHIBITO RS
The nonsteroidal anti-inflammatory agents inhibit lhe synthesis of prostaglandins and are classified as prostaglandin synthetase inhibitors (PGS I). In addition to inhibiting the prostaglandin synthetase enzymes. some of the inhibitors also have prostaglandin antagonist properties; that is , they block the action of prostaglandins on the target tissue. namely the myometrial cells in the case: of primary d ysmenorrhea . It has been suggested that the nonsteroidal anti-inflammatory drugs which are prostaglandin S}'Y\l~tase inhibitors can be divided into 2 groups, the type I prostaglandin inhibitors and type 2 inhibitors. The type I inhibitors inhibit the action of cyclo-oxygenase , which is the enzyme that catalyses the conversion of arachidonic acid to cyclic endoperoxides. while the type 2 inhibitors inhibit the action of the enzymes isomerase and reductase which mediates the conversion of cyclic endoperoxides to PGE2 and PGF2 a . Examples of type: I inhibitors are the fenamates, aryl propionic acid derivatives and the indoleacetic acid derivativ'Cs. Examples of the type 2 inhibitors are phenyl butazone and p-mcrcurochlorobcn7oate . Since the type I prostaglandin inhibitors block the biosYnlhesis of both C)'elie endopc:roxides and PGE2 and PGF2 Q • a g~ater efficac), can be expected in the treatment of primary d),smenorrhea with type I inhibitors rather than type 2 inhibitors. This is because c),c1ic endopcroxides have strong uterot onic properties and sensitize the nerve terminals to the chemiclil and physical stimuli of pain .
There are 5 major categories of nonsteroidal antiinnammatory drugs which are prostaglandin synthetase inhibitors. These fi\'e categories arc based on the chemkal Slructu~ of the compounds.
a. Benzoic Add D erivatives
An example of a benzoic acid derivative is the well known compound aspirin or acetylsalicylic acid. In two of three clinical trials, aspirin in doses of 650mg ever)' SIX hours during the first 2 to 3 days of the menstrual phase was not significantly bette r than a placebo l • ,IS (table 4) However, in one study performed on adolescents. a spirin in doses of650mgevery6 hours commencing I day before the onset of menstruation appeared to produce belleT relief than a placebo I •. Thus. at p~sent the effK:aCY of aspirin in the lrealmenl of primary dysmenorrhea remains 10 be proven. Tbedivergent results reported to date could be related to the dose of aspirin used and the time of administration. Add itionally, aspirin has been shown be be ineffective in vilrO in inhibiting prostaglandin synthetase but is active in vivO. This has been attributed to the metabolic transforma tion of aspirin to gentisic acid which is the active co mponent for inhibition of prostaglandin synthetase l • .
b . Buterophenones
Examples of compounds with Ihis structure are phenylbutalone and oxyphenbutalone. These are type 2 inhibitors aod wouJd therefore be less desirable as a prostaglandin inhibitor of first choice amongst the non-steroidal anti-inflammatory drugs in the treatment of primary dysmenorrhea . Additionally these compou nds can potentially produce serious side effects such as blood dyscrasias.
c. IndolHcetic A cid Deri vatives
An example of this group is indomethacin. Indomethacin bas been shown to be significanlly better than placebo in the treatment of primary dysmenorrhea . Relief has been obtained in 73 to 90 percent of patieolS IU9 .1ndomethacin has been shown to suppress prostaglandin production and release in endomelriallissue as well as suppress uterine activity, thus relieving uterine ischaemia and the symptoms of primary dysmenorrhea .
d . Fenamates
Examples of these deri"alives are the fenamicacids 20 ,12. Pretreatment before the onset of menstruation is not necessar)' with the fensma tes. It is claimed that the fenamates have prostaglandin antagonist proper1ie~. HO'o'"t:ve r, in chnical trials, the reLlef rate obtained is no different from the arylpropionic acid derivative or the iduleacetic acid deriva tive groups of prostaglandin synthetase inhibitors. One consideration in the usc of merensmic acid is the lack of long term safety datil when compared to M)me of the aryipropionic acid derivatives such us ibuprofen.
e. Aryipropionic Acid Derivatives
These include compou nd s such as ibuprofe n, na· proxen. naproxen sodium, suprofen and ketoprofen. ~aproxen and ibuprofen have been extensively tested for their efficacy in primary dysmenorrhea and in many clinica l trials have been shown to be highl)' effective with an efficacy rate ranging from 66 to 100 pcrccnt1.9,I\llJO. Onl)' one stud)' has bee!"! carried out using ketoprofen which shows that it is significant ly better than placc:bo)1 With ibuprofen and naproxen there is an accompanying reduction in prostaglandin levels in the menstrual fluid or uterine jet washings with a concomil.an t reduct ion in uterine activity and relief of the symptoms of primary dysmenorrhea. With ibuprofen and naproxen pretreatment beforC' the onset of menstruation is not necessar)' and treatment need only be given for the first 2 to 3 days of the menstrual period.
£. Eflect of Treatment on Menstrual Fluid Prostaglandins (1) Prostaglandin Synthetase InhibitOR
The prostaglandin synthetase inhibitors which are nonsteroidal anti.infiammatory drugs also ha ve direct analgesic properties . Thus. at present it is unclear whether the relief of dysmenorrhea by these drugs is purely due 10 the supression of menstrual fluid prostaglandins or to a direct analgesic effect or a combination of both. In most clinical trials on the efficacy of the nonsteroidal anti·inflammatory drugs in relie\·ing primary dysmenorrhea, assessmenl has been made only o n a clinical and subjective basis for the relief of pain . Three of the prostaglandin synthetase inhibitors, indomethacin. ibuprofen and naproxen, have been shown to reduce endometrial prostaglandin levels during treatment of primary d)'sm~norrhea with these drugs. With ibuprofen, there IS a significan t reduction 10 the amount of prostaglandins released in the menstrual fluid to below normal le .... els, but without an accompanying reduc tion in the menstrual nuid volume. Thus the reduction in menstrual fluid prostaglandins appears to be: a direct suppression of the biosynthesis of prostaglandin in the endometrial tissue. Ln contrast. in women with an intrauterine device tterc isa reduction in dysmenorrhea as well as L reduction in the menstrual blood loss when a prostaglandin synthetase inhibitor such as flufenamic acid or ibuprofen is givenll ,H . The reduction In menstrual fluid prostaglandin is due to the suppression of prostaglandin production and release which normally occurs during the first 48 houT$ of menstruation'. ( 2) The Oral Contraceptive Pill
The combined estroge n·progesterone oral contraceptive pill is effective in relieving primary dysmenorrhea and has been the mainstay of treatment si nce its introduction. There is a reduction in menstrual fluid prostaglandins to below normal levels in women using the oral contraceptive pill and suffering from primary dysmenorrhea. This reduction is probably the result of two mechanisms: I) a reduction in the menstrual nuid volume which accompanies the use of birth control pills, since the endometrial tissue growth is suppressed and therefore menstrual loss is reduced and 2) the suppression of ovu lation which results in an a novulatory cycle. and an endocrine mileau which is essentially similar to the early proliferath'e phase of the menstrual cycle when prostaglandins are at the lowest level and luteal phase progesterone levels are ab~nt.
Thus both oral co ntra cep tives and the prostaglandin syn theta se inhibitors su ppress menstrual fluid prostaglandin levels resulting in relief of primary dysmenorrhea although through somewhat different mechanisms .
g. Drug Dosages
The doses of nonsteroidal anti·inflammatory drugs used for treatment of primarydysmenorrheaaregi .... en in table 4 . In most of the studies, it is apparent that The rapidity with whicb tbe drug is absorbed determines the rapidity with which relief of dysmenorrhea is obtained. With rapidly absorbed drugs such as ibuprofen, naproxen or naproxen sodium. there is no significant difference in the menstrual nuid prostaglandin levels whether the drug is taken for J days before the onset of menses or if the drug is commenced at the onset of menstrual no~. The rationale for giving prostaglandin synthetase inhibitors for 48 hours is based on the observation that prostaglandin production and release is maximal during the first 48 houn of the menstrual now. as has bttn shown in studies (rom our laboratory' . ' .
U the response to treatment during the first cycle indicates that some degree of uterine cramps penist during the first hour or so of beginning oral medication. then it is recommended that the starting dose be increased by 50 percent or doubled at the next cycle wh ile keeping the maintenance dose essentially the same as before. Thus. with ibuprofen for example if the response to 400mg 4 times daily is un58tisfactory a loading dose of 600mg at the onset of menSlrua l flow may be tried before increasing the loading dose to 800mg at the next cycle. if necessary. The maximum tolerated dose for ibuprofen as recommended by the manufacturers is 24OOmg. It is seldom necessary to give women with primary d~men orrhea more than 2000mg of ibuprofen per day.
h. Contraindicatlons
One contraindication to the use of prostaglandin synthetase inhibitors is the presence of gastrointestinal ulcers. A1lhough some of the more recently developed prostaglandin syntheta se inhibitors have a lower ulcerogenic index than some of the earlier compounds. at present it is probably prudent to avoid administering these drugs to patients with a definite history of gastric and duodenal ulcers. Prostagla nd in synthetase: inhibitors should be taken with milk . A relative contra indicatIon is a previous history of a bronchospaslic type of reaction after the ingestion of aspirm drugs. Adverse reactions to mefenamic acid include nausea. gastrointestinal discomrort . vomiti ng. flatulence and diarrhea . severe autoimmune hemolytic anemia . drowsiness, dizziness. nervousness. headache , blu~ vision. rash. renal toxici ty. and mIld hepatic toxicity. In animal s tudies mefenamic acid decre~ fertility and in rabbits it increases the number of fetal resorptions.
(3) Ibuprofen
Side effects of ibuprofen include gastrointcstinal intolerance. skin rashes . dizziness. nuid retenlion and edema. Ibuprofen is contraindicated In patients who hue nasal polyps or angi~dema. bronchospastic react ivity to aspirin, or gastrointcstinal ulcers . In animal studies. ibuprofen up to l600mg daily d id not reveal any evidence of teratogenic effect . Howevcr. if is prudent not to administer ibuprofen in suspected pregnancy.
(4) Naproun
The side effects ofnaproxen as used in the treatment of primary dysmenorrhea are considerably less than those associated with indomethacin . Side effects of naprolten may include gastrointestinal d isturbances. drowsiness, tiredness, headache and dryness of the mouth but no serious side effects have been reponed with this drug in the lreatment of primary dysmenorrhea.
Other side effects of prostaglandin syn thetase inhibitors include those givcn in table S. ( 
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On) Contnceptivts
The side effects of the combi ned contraceptive pill are well known and need not be listed here. 
CLINICAL MANAGEMENT OF PRIMARY DYSMENORRHEA
It is essential that the physician spends time talking to the patien t, explaining about the disorder and what can be expected from the modern approach to treatment of primary dysme norrhea, regard less of the medication chosen. If such a dialogue is carried out in the correct manner, it will have psychotherapeutic benefit to the patient with respect to her response to pain and thus improve the outcome of the pharmacotherapy. An outline of the management of primary dysmenorrhea is given in table 6 . The chotee of medication will depend on whether the woman requires an oral contraceptive for birth control, and if there is any contraindica tion to the use of a combined oral contraceptive or the use of a prostaglandin synt hetase inhibi tor. Thus, if the patient wants birth control with the combined oral contraceptive, this would be the drug of choice in the treatment of primary dysmenorrhea in this category of women . The effcct of the oml cont raceptive pill is to inhibit ovula tion, rtduce endometrial growt h a nd therefore menstrual fluid volume, with an accompanying reduction in menstrual fluid prostaglandins (see above). Relief of primary dysmenorrhea can be obtained in at least 90 percent or more of women with primary dysmenorrhea and a trial of the oral contraceptive for a period of 3 months is worthwhile.
If the patient responds to the ora l contraceptive. she can then be maintained on this regimen. If the patient does not wish to use a n oral contraceptive as a method of birth control, the drug of cboice for the treatment of primary dysmenorrhea is a prostaglandin synthetase inhibitor. This form of thera py has adva ntages over birth control pills. as treatment is restricted 102 to 3 days of the menstrual cycle, whereas the oral contraceptive has to be given for a minimum of3 weeks out of 4. In addition there is no significant suppression of the pituitary-ovarian ax is and there are none of the metabolic effeeLS which are seen with the oral contraceptive. The choice of prostaglandin synthetase inhibitor has been referred to above. A trial with prostaglandin inhibitors of up to 6 months duration with the necessary changes in dosage or the type of inhibitor, should the one chosen nOt work effectively, will be sufficie nt to show whether or not relief will be obtained.
If the patient docs nOI respond to a prOStaglandm synthetase inhibitor, then it is appropria te to reconsider whether pelvic pathology which is not palpably detectable and which co nstitu tes seconda ry d ysmenorrhea may ha ve been missed . At this point , a laparoscopy should probably be performed to rule out or confirm a pelvic disease. In the event that a pelvic d isease is discovered, then the appropnate trea tment will be directed to\\ard the underlying pathology and the d ysmenorrhea shou ld a l the same time be alleviated . If a pelvic pathology is not found, it is at present unclear whether any pharmacologica l agent could be: of help to these pat )ents. Pat ie nts whodo not have any demonstrable pelvic pathology on laparoscopy, and who ha ve not responded toeithe r an oral contrace pt ive, a prostaglandin synthetase in hibito r or a rou tine analgesic. shou ld be given a trial of a B-sympathom imetic agent such as isollSuprine hydrochlo ride. terbuta li ne sulphate or ri todri ne hyd rochloride. If no sat isfactory res p om~e is ob!a ined. the n referral fo r psychiatric treatment ma y be appropriate . 
